CAR T-cell therapy has revolutionized treatment for many blood cancers. However, the benefits of its use in the early stages of care remain uncertain. Chimeric antigen receptor (CAR) T-cell therapy ...

CAR T-cell therapy re-engineers immune cells to target and eradicate high-risk blood cancers, offering potential cures where traditional chemotherapy fails. Initially requiring inpatient care due to ...

This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...

CAR-T cell therapy has cured some children with blood cancers and is being studied in solid tumors, where responses differ due to how these cancers grow. CAR-T cell therapy has cured some children ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...

Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...

Please provide your email address to receive an email when new articles are posted on . Multiple CAR T-cell therapy strategies have exhibited clinical activity in recurrent glioblastoma. Early data ...

FDA approval criteria primarily dictate the sequencing of multiple myeloma therapies, often restricting bispecific antibodies to later treatment lines. Institutional practices vary in using CAR T-cell ...

A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.